Clinical Takeaway
Trauma-focused treatments remain effective for PTSD even in patients who use cannabis, including those with co-occurring substance use disorders. Cannabis use at baseline does not appear to undermine the benefit of evidence-based PTSD interventions, supporting their use in this population without requiring cannabis abstinence as a precondition for care.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis addresses a critical clinical gap by examining whether evidence-based trauma-focused treatments remain effective for the substantial subset of PTSD+SUD patients who use cannabis, a population typically excluded from or underrepresented in efficacy trials. The findings directly inform treatment selection and prognosis counseling for clinicians managing the common comorbidity of PTSD, substance use, and cannabis use. Understanding treatment efficacy stratified by cannabis use status enables more precise risk-benefit assessment and individualized care planning for this high-risk population.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 While this meta-analysis addresses a clinically important gap by examining trauma-focused treatment outcomes in cannabis users with co-occurring PTSD and substance use disorders, several limitations warrant careful interpretation. The analysis draws from only four RCTs nested within a larger project, which constrains generalizability and statistical power for detecting meaningful subgroup differences, and the individual patient data approach, while methodologically rigorous, cannot fully account for variations in cannabis potency, frequency, route of administration, or temporal relationship to treatment. Confounders such as whether cannabis use preceded or followed PTSD onset, concurrent use of other substances, medication adherence, and treatment engagement remain difficult to isolate in retrospective meta-analytic work. Clinically, this research suggests that active cannabis use should not automatically exclude patients from evidence-based trauma-focused therapies, but practitioners should maintain heightened attention to treatment response, actively assess cannabis as a potential avoidance or self-medication behavior, and consider integrated care approaches that address both PTSD symptoms and cannabis